News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
494,726 Results
Type
Article (23001)
Company Profile (105)
Press Release (471620)
Section
Business (148156)
Career Advice (780)
Deals (27204)
Drug Delivery (90)
Drug Development (60122)
Employer Resources (84)
FDA (13920)
Job Trends (10538)
News (255271)
Policy (24839)
Tag
Academia (1230)
Alliances (39272)
Alzheimer's disease (819)
Approvals (13938)
Artificial intelligence (145)
Bankruptcy (214)
Best Places to Work (8508)
Biosimilars (95)
Breast cancer (138)
Cancer (1251)
Career advice (665)
CAR-T (109)
Cell therapy (324)
Clinical research (49489)
Collaboration (543)
Compensation (186)
COVID-19 (1768)
C-suite (130)
Data (1338)
Diabetes (185)
Diagnostics (4503)
Earnings (61353)
Events (70309)
Executive appointments (446)
FDA (14739)
Funding (410)
Gene therapy (214)
GLP-1 (495)
Government (3077)
Healthcare (11454)
Infectious disease (1853)
Inflammatory bowel disease (91)
Interviews (101)
IPO (12289)
Job creations (2395)
Job search strategy (597)
Layoffs (302)
Legal (4915)
Lung cancer (198)
Manufacturing (262)
Medical device (10874)
Medtech (10878)
Mergers & acquisitions (15268)
Metabolic disorders (421)
Neuroscience (1101)
NextGen: Class of 2025 (3854)
Non-profit (1494)
Northern California (1610)
Obesity (223)
Opinion (149)
Patents (143)
People (39888)
Phase I (15186)
Phase II (21537)
Phase III (17049)
Pipeline (687)
Postmarket research (1603)
Preclinical (5847)
Radiopharmaceuticals (187)
Rare diseases (220)
Real estate (4380)
Regulatory (18318)
Research institute (1173)
Resumes & cover letters (93)
Southern California (1386)
Startups (2530)
United States (14026)
Vaccines (430)
Weight loss (151)
Date
Today (124)
Last 7 days (598)
Last 30 days (2074)
Last 365 days (25931)
2025 (4065)
2024 (26692)
2023 (30914)
2022 (41087)
2021 (43908)
2020 (41693)
2019 (32758)
2018 (25072)
2017 (26049)
2016 (23972)
2015 (28430)
2014 (20600)
2013 (17151)
2012 (18752)
2011 (19536)
2010 (17102)
Location
Africa (447)
Arizona (96)
Asia (36298)
Australia (5108)
California (3624)
Canada (1278)
China (430)
Colorado (153)
Connecticut (167)
Europe (66596)
Florida (522)
Georgia (136)
Illinois (323)
Indiana (218)
Japan (109)
Maryland (604)
Massachusetts (2582)
Michigan (190)
Minnesota (218)
New Jersey (1200)
New York (1057)
North Carolina (635)
Northern California (1610)
Ohio (137)
Pennsylvania (843)
South America (803)
Southern California (1386)
Texas (490)
Utah (92)
Virginia (91)
Washington State (338)
494,726 Results for "china biologic products".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
February 4, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
China
The Rise of China Innovation in the Time of Trump
With incoming president Donald Trump threatening a trade war with China, experts told
BioSpace
that the new administration will likely understand why medicines should be treated differently.
January 16, 2025
·
4 min read
·
Annalee Armstrong
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
Press Releases
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
January 29, 2025
·
4 min read
Earnings
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
February 4, 2025
·
4 min read
·
Annalee Armstrong
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced that the Biologics License Application for Lonapegsomatropin was accepted by the China National Medical Products Administration.
March 7, 2024
·
2 min read
Press Releases
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
February 25, 2025
·
3 min read
Press Releases
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
March 3, 2025
·
3 min read
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
InnoCare Pharma announced today that China National Medical Products Administration (NMPA) has accepted and granted priority review to a biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
June 20, 2024
·
4 min read
1 of 49,473
Next
